Login to Your Account

Nouscom closes $49M series B for off-the-shelf personalized cancer vaccines

By Cormac Sheridan
Staff Writer

Monday, November 6, 2017

BERLIN – Nouscom AG announced its presence on the opening day of the BIO-Europe Fall meeting with news of a €42 million (US$48.8 million) series B round that will enable it to move its distinctive viral vaccine approach to cancer immunotherapy into clinical trials.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription